2017

The I.M. Rosenzweig Junior Investigator Award Winners​

The I.M. Rosenzweig Junior Investigator Award was established to encourage researchers to maintain and enhance their interest in PF research during the early stages of their academic career. 

Steve M. Albelda, MD

Apr 20, 2021, 12:50 PM
Title : Steve M. Albelda, MD
First Name : Steve
Middle Name : M.
Last Name : Albelda, MD
Position :
University : The Trustees of the University of Pennsylvania
Proposal Title : "Use of T cells Directed to Fibroblast Activation Protein to Treat Pulmonary Fibrosis"
Proposal Funder : Boehringer Ingelheim Pharmaceuticals, Inc.
Dr. Albelda is the William Maul Measey Professor of Medicine, Associate Director of the Pulmonary Division, Director of the Thoracic Oncology Research Laboratory, and co-director of the Translational Center of Excellence for Lung Cancer at Penn.

Despite the recent approval of perfenidone and nintedanib to slow the progression of idiopathic pulmonary fibrosis (IPF), there is no way to reverse the established scarring (fibrosis). A key factor in IPF is production of excess scar tissue by a cell type known as fibroblasts, which normally function in wound healing. Dr. Albelda’s team proposes to use a new technology that they developed for the treatment of cancer that can genetically redirect blood cells (lymphocytes) to attack “scar-producing” activated fibroblasts in the fibrotic lung. The research team will test this approach in three mouse models of lung fibrosis. If successful and safe, this study will pave the way toward clinical trials that could change the treatment paradigm for IPF and potentially reverse lung scarring and improve lung function.
Load more comments
Comment by from

The Albert Rose Established Investigator Award Winners

Created to allow established investigators to explore novel, innovative areas of research, the Albert Rose Established Investigator Award provides critical support to the development of new projects, and enables the investigator to pursue additional funding through the National Institutes of Health or other agencies. Two $50,000 grants are awarded per annual cycle, disbursed over a two-year period.

Steve M. Albelda, MD

Apr 20, 2021, 12:50 PM
Title : Steve M. Albelda, MD
First Name : Steve
Middle Name : M.
Last Name : Albelda, MD
Position :
University : The Trustees of the University of Pennsylvania
Proposal Title : "Use of T cells Directed to Fibroblast Activation Protein to Treat Pulmonary Fibrosis"
Proposal Funder : Boehringer Ingelheim Pharmaceuticals, Inc.
Dr. Albelda is the William Maul Measey Professor of Medicine, Associate Director of the Pulmonary Division, Director of the Thoracic Oncology Research Laboratory, and co-director of the Translational Center of Excellence for Lung Cancer at Penn.

Despite the recent approval of perfenidone and nintedanib to slow the progression of idiopathic pulmonary fibrosis (IPF), there is no way to reverse the established scarring (fibrosis). A key factor in IPF is production of excess scar tissue by a cell type known as fibroblasts, which normally function in wound healing. Dr. Albelda’s team proposes to use a new technology that they developed for the treatment of cancer that can genetically redirect blood cells (lymphocytes) to attack “scar-producing” activated fibroblasts in the fibrotic lung. The research team will test this approach in three mouse models of lung fibrosis. If successful and safe, this study will pave the way toward clinical trials that could change the treatment paradigm for IPF and potentially reverse lung scarring and improve lung function.
Load more comments
Comment by from